In this article, we will discuss about Afatinib (Dosage Overview). So, let’s get started.
Afatinib (GILOTRIF®) is a kinase inhibitor indicated for:
First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Limitation of Use: Safety and efficacy of Afatinib (GILOTRIF®) were not established in patients whose tumors have resistant EGFR mutations.
Afatinib (GILOTRIF®) is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.
• Recommended dose: 40 mg orally, once daily
• For patient’s with Renal impairment: 30 mg orally, once daily in patients with severe renal impairment. Afatinib (GILOTRIF®) to be taken least 1 hour before or 2 hours after a meal.